View all news

eRAPID becomes a multicentre study

Members of the eRAPID team: (L-R) Kerry Avery, Jane Blazeby, Hollie Richards

7 June 2017

Developing an electronic platform to monitor symptoms and generate adverse event alerts and patient feedback after discharge following upper gastrointestinal surgery for cancer: the electronic patient-reporting of adverse events (eRAPID) feasibility study.

Surgery for upper gastrointestinal (UGI) cancer is associated with major morbidity.  Some of this occurs after hospital discharge and prompt identification of serious adverse effects (AEs) is importnat to improve outcomes.  The eRAPID feasibility study aims to develop an online questionnaire integrated within routine electronic patient records for patients to self-report AEs after discharge for UGI cancer surgery.  Currently, we are in the process of developing the system to generate automatic online patient self-management feedback and/or advice to contact a healthcare professional or, for concerning symptoms, trigger healthcare professional email alerts to contact the patient. We will then evaluate the feasibility and acceptability to patients and healthcare professionals.

eRAPID is also used in two other centres but in different disease areas: Leeds (systematic treatment and Manchester (radiotherapy).  So far, the eRAPID UGI study has been a single centre feasibility study, with 45 patients recruited at University Hospitals Bristol NHS Foundation Trust.  We are very pleased to say that we now have a new centre joining the study.  As of today, our colleagues at Birmingham Heartlands Hospital, comprising a team of research nurses, cancer nurse specialists and UGI surgeons, will begin recruiting to the eRAPID study.  We wish them luck!



Further information

If you have any further questions or have any suggestions then we would love to hear from you.  You can email

Our newsletter is also available to read here eRAPID newsletter (PDF, 713kB)